ABLYNX RECEIVES MILESTONE PAYMENT AS PART OF ITS STRATEGIC ALLIANCE
WITH BOEHRINGER INGELHEIM

(Thomson Reuters ONE) - GHENT, Belgium, 1 October 2009 - Ablynx [Euronext Brussels: ABLX],today announced that it will receive milestone payments totalling ?3million from Boehringer Ingelheim triggered as part of its strategicalliance for the development and commercialisation of Nanobodies®.This is the second time Ablynx receives milestone payments fromBoehringer Ingelheim since the initiation of the strategic alliancebetween the companies.Ablynx and Boehringer Ingelheim entered into an agreement inSeptember 2007 to collaborate on the discovery, development andcommercialisation of up to 10 different Nanobody® therapeutics acrossa range of multiple therapeutic areas including for exampleimmunology, oncology and respiratory diseases. The agreement wouldallow potential milestone payments of up to ?125 million for eachNanobody® developed as well as undisclosed royalties to Ablynx.Boehringer Ingelheim is exclusively responsible for the development,manufacture and commercialisation of any products resulting from thecollaboration. Ablynx retains certain co-promotion rights in Europe.Dr Edwin Moses, CEO and Chairman of Ablynx, commented:"Our strategic alliance with Boehringer Ingelheim is developing welland these milestone payments are further evidence of importanttechnical achievements. We are particularly pleased that twomilestones have been achieved this year and we anticipate makingfurther such progress in the near future. We look forward tocontinuing our efforts in this strategic alliance with BoehringerIngelheim with the goal to develop and commercialise Nanobodiesacross multiple therapeutic areas." -ends-For more information, please contact:For international media enquiries:College Hill Life SciencesSue Charles, Justine Lamond,Dr John McIntyret: +44 (0)20 7866 7857e: ablynx(at)collegehill.comAblynx:Dr Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comUEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comUhttp://hugin.info/137912/R/1345289/322874.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 01.10.2009 - 18:00 Uhr
Sprache: Deutsch
News-ID 6508
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 287 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ABLYNX RECEIVES MILESTONE PAYMENT AS PART OF ITS STRATEGIC ALLIANCE
WITH BOEHRINGER INGELHEIM"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx